CRESTOR’S® Debut to Market

September 6, 2013

Our client, Shionogi & Co., Ltd., developed a heterocyclic compound named Rosuvastatin, discovered to be uniquely effective in the treatment of high cholesterol. Like LIPITOR®, Rosuvastatin is a “statin,” effective in reducing cholesterol and triglyceride levels. Wenderoth helped Shionogi obtain the U.S. patent for Rosuvastatin, which is now marketed worldwide by AstraZeneca as CRESTOR®. From 2006-2013, CRESTOR® generated over $37 billion in worldwide sales, and was the most commonly prescribed cholesterol medication in 2013.